KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS Apr 28, 2025
KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO PIVOTAL US PHASE III CLINICAL TRIALS FOR TG-C Jul 11, 2024